Exicure reports Q1 net loss of $0.8M; cash only $0.2M by May 31, going concern

EXICURE, INC.

Cash and equivalents $0.4M at March 31, 2024, falling to ~$0.2M by May 31.
Received $0.7M loan from DGP Co., Ltd. after May 31; 6% interest, 10-month maturity.
Revenue of $0.5M from patent license for cavrotolimod (hepatitis) with private biopharma.
Net loss improved to $0.8M from $4.4M YoY due to cost cuts and license revenue.
Company states existing cash insufficient; substantial near-term financing needed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.